Theophylline
80. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK571, a potent leukotriene D4receptor antagonist. N Engl J Med 1990; 323: 1736-9. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1984; 74: 617-22. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834-46. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599600. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Rev Respir Dis 1992; 146: 96-103. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Rev Respir Dis 1991; 143: 1025-9. Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992; 119: 48-51. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48: 1205-10. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52: 523-7. Spector SL, Smith LJ, Glass M, Accolate Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. J Respir Crit Care Med 1994; 150: 618-23. Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast MK0476 ; , a new potent cysteinyl leukotriene LTD4 ; receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528-34. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059-66. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996; 275: 931-6. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-liopxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859-71. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998; 158: 1213-20. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424-8. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998; 279: 1181-6. Noonan MJ, Chervinsky P, Brandon M. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998; 11: 1232-9. Global initiative for asthma: global strategy for asthma management and prevention: NHLBI WHO Workshop report. Bethesda, Md.: National Heart, Lung, and Blood Institute, January 1995. NIH publication no. 953659. ; 99. Guidelines for the diagnosis and treatment of asthma. Expert panel report 2. Clinical practice guidelines. Bethesda, Md.: National Asthma Education Program, April 1997. NIH publication no. 97-4051. ; 100. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062-3. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. J Respir Crit Care Med 1997; 155: 1235-40. Singulair montelukast sodium ; . West Point, Pa.: Merck, 1998 package insert ; . 103. Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. J Respir Crit Care Med 1995; 152: 1203-7. Schwartz HJ, Petty T, Dube LM, Swanson LJ, Lancaster JF. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. Arch Intern Med 1998; 158: 141-8 Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455-7. Tion does not affect the activity of PDE4 on hydrolyzing cAMP[10]. In this study, the extract of GL62 yeast cell had little hydrolyzing effect on cGMP. PDE4A activity on cAMP also was not influenced when cGMP existed in the reaction system. At the concentration of 10 mol L and 100 mol L, cGMP did not affect the PDE4A hydrolyzing-cAMP activity of the extract Fig 3 ; . These suggest that the extract selectively hydrolyze cAMP and that cGMP is not the specific substrate of the extract. T heophylline is one of non-selective PDE inhibitors, which inhibits all members of the PDE family including PDE4. Rolipram is one of the second generation PDE inhibitors, which only inhibits PDE4, including PDE4A, PDE4B, PDE4C, and PDE4D[11]. In this study, the PDE4A activity was inhibited by theophylline and rolipram both in a concentration-dependent manner. Rolipram inhibited the PDE4A activity of the extract more strongly than theophylline. It is suggested that the expressed product of GL62 is PDE4A. Acetamide-45, N- Pyridin-4-yl ; -[1- 4-fluorophenyl ; indol-3-yl]acetamide, was reported as a new antiinflammatory drug[12]. It has been introduced recently that acetamide-45 inhibited the ovalbumin-induced histamine release from peritoneal mast cells, the IL-4 and IL-5 production of Th2 lymphocyte, and the activation of eosinophil[12]. It was also reported that acetamide45 inhibited the contraction of isolated guinea pig trachea induced by histamine and methacholine[13 ]. But the mechanism remains unknown. The present study showed that acetamide-45 had inhibitory effect on PDE4A activity of the expressed product. The nature of this inhibition varied with concentration. At a concentration of 110-5 mol L, acetamide-45 caused feeble depression of hydrolysis of cAMP. However, when the concentration rose to 310-5 mol L, acetamide-45 inhibited the PDE4A activity significantly. At a concentration of 310-4 mol L, acetamide-45 achieved the maximal effect that the remaining activity was 52 % 5 %. The study of higher concentrations was not carried out because of limited dissolution of the compound. Acetamide-45 inhibited the activity of PDE4A stronger than theophylline, but weaker than rolipram Tab 2 ; . So suggested that acetamide-45 may be an effective PDE4 inhibitor and the anti-inflammatory effect of the drug may depend on inhibition of PDE4. In conclusion, the present studies indicate that PDE4A can be expressed in yeast cell GL62 induced by CuSO4, and that acetamide-45, a kind of new anti-in.
Drug theophylline medication
TABLE 5. Histamine resistance of pertussis-senisitized or propranolol-pretreated mice after administration of theophylline, epinephrifle, or 3', 5'-AMP.
The solid state of the active pharmaceutical ingredient may influence the pharmaceutically relevant physicochemical properties including the dissolution rate, flowability, compressibility, and stability both physical and chemical ; . Conventionally, material characterization studies are restricted to the raw materials. Phase transitions may occur during the various processing steps involved in the preparation of a pharmaceutical formulation ie, milling, granulation, drying, and compaction ; and also at the time of storage. In recent years, there has been an increased regulatory interest to characterize and to control the physical form of active pharmaceutical ingredients in dosage forms.1 In pharmaceutical materials, phase transitions are often mediated by water. Water can associate with solids in a variety of ways. In case of hydrates, water is usually incorporated in the lattice in stoichiometric proportions. Water may also be adsorbed on the solid surface or sorbed in the disordered regions of the lattice. In the latter case, the amount of water held is variable and depends on the method of preparation of the solid and storage conditions. Distinguishing between the different states of water in solids is an analytical challenge. There are 2 commonly used methods for determination of water content in solids--Karl Fischer titrimetry and thermogravimetry. Both these methods are suitable to quantify the total water in a sample and do not readily distinguish between sorbed physically bound ; and lattice water. The water-solid interaction is expected to be much stronger when water exists in the crystal lattice in stoichiometric proportions, rather then in a sorbed state. If water removal is performed under carefully controlled conditions, it might be possible to differentiate between the physically bound and lattice water in a crystalline solid. Moreover, the activation energy for water removal is expected to be different for the 2 cases and albenza.
The vasodilatory effects of dipyridamole are abolished by administration of the adenosine receptor antagonist theophylline.
A central mechanism appears to be responsible for theophylline's ability to reduce central sleep apnea in patients with heart failure and albendazole.
BRONCHODILATOR RESPIRATORY INHALANTS * fluticasone pirbuterol flunisolide salmeterol ipratropium terbutaline metaproterenol theophylline montelukast tiotropium nedocromil triamcinolone oxtriphylline zafirlukast zileuton * Solutions for nebulizers are not covered. SINUSITIS acrivastine-pseudoephedrine clemastine phenir-ppa-phenylt.-pyrilamine azatadine phenylephrine-promethazine brompheniramine w wo combinations dexchlorpheniramine phenylprop-pyril-pheniramine budesonide diphenhydramine phenyltolox-APAP carbinoxamine fexofenadine phenyltolox-pyril-pheniramine cetirizine mometasone promethazine chlorpheniramine w wo combinations naphazoline w wo combinations triprolidine OPHTHALMOLOGY acetylcholine dipivefrin medrysone apraclonidine dorzolamide metipranol atropine dorzolamide-timolol pilocarpine brimonidine ecothiopate prednisolone brinzolamide homatropine rimexolone carbachol latanoprost timolol cyclopentolate levobunolol tropicamide w wo hydroxyamphetamine cyclopentolate-phenylephrine loteprednol INSULIN acarbose glyburide repaglinide acetohexamide insulin rosiglitazone chlorpropamide metformin tolazamide glimepiride miglitol tolbutamide glipizide pioglitazone ANCILLARY DEVICES glucose monitor - limit one lancets lancet devices spacers aerochambers glucose test control solution peak flow meter syringes needles glucose test strips albuterol albuterol-ipratropium beclomethasone bitolterol budesonide cromolyn dyphylline Reimbursable only with a prescription for an injectable drug covered by ADAP. INFLUENZA amantadine oseltamivir rimantadine zanamivir ANTIRETROVIRAL THERAPY tipranavir Aptivus ; enfuvirtide Fuzeon, T-20 ; PCP & TOXOPLASMOSIS atovaquone Mepron ; HEMATOLOGICAL INDICATIONS epoetin alfa filgrastim sargramostim immune globulin Rho Win Rho SDF ; oprelvekin Neumega ; GYNECOLOGICAL estrogens estrogens-progestins progestins DRUGS REQUIRING PRIOR AUTHORIZATION Call 1-800-832-5305 to initiate the prior authorization process. Call 1-800-832-5305 to initiate the prior authorization process. Third line prophylaxis or treatment for PCP and Toxoplasmosis, due to high cost. For AIDS related anemia, with: Hct 30% and or Hgb 10g dl. For severe neutropenia due to: chemotherapy; or drug toxicity or HIV disease. With ANC 500 mm3. For HIV-associated thrombocytopenia; with platelets 20, 000 mm3. Prior authorization is not required for children. For chemotherapy induced thrombocytopenia; with platelet count 20, 000 ul. and or documented risk factors or clinical indications. URINARY INCONTINENCE flavoxate oxybutynin tolterodine.
We have explained before that criticisms of the quality of mammograms in the study are unwarranted not only because of the excellent mammographic sensitivity achieved in the second Canadian national breast screening study, 2 but also because of rates of cancer detection that even now are not being exceeded in programmes using "modern mammography."3 4 In the second study, for women allocated to receive mammography and clinical breast examination, the detection rate at first screen was 7.2 1000, and at subsequent screens 3.0 1000. Mammography alone or together with physical examination detected 76% and 84%, respectively, of these cancers. But perhaps most telling is that for small invasive cancers smaller than 15 mm in size ; , the rate at the first screen was 1.8 1000 and at subsequent screens 1.1 1000. Furthermore, of 267 invasive breast cancers found in our mammography arm by screening, 126 47% ; were found by mammography alone. In spite of mammography detecting small cancers two to five years earlier compared with when the catchup occurred in women screened by physical examination alone, and in spite of mammography detecting more breast cancers, there was no effect on the breast cancer death rate after 13 year follow up.3 Obviously mammography in the second Canadian national breast screening study found small cancers with a "good prognosis, " which probably grow slowly and are easy to treat even if they are found later by skilled physical examination by a health professional or by self examination. Unfortunately, the mammographically detected cancers with a "good" prognosis do not affect mortality from breast cancer. Many will not be persuaded by such arguments, especially those who believe the second Canadian study was designed to evaluate the efficacy of breast screening in this age group and disregard the fact that it was designed solely to evaluate the incremental benefit of mammography over and above clinical breast examination. For that reason, we enthusiastically support the call by Mittra et al for a randomised trial comparing mammography with physical examination, to which we would add self examination of the breast, as there is evidence from other analyses of the Canadian study that self examination does contribute to a reduction in mortality from breast cancer if done well.5 and spironolactone.
Theophylline or aminophylline
Normal serum theophylline range
Subject population the potential for severe interactions was lessened, because drugs known to have both a narrow therapeutic margin and high potential for metabolic interaction were not commonly used. These include the tricyclic antidepressants, theophylline, phenytoin, tolbutamide, carbamazepine, terfenadine, astemizole, Type IC antiarrhythmics, and antipsychotics.5 Alternatively, it may be that recent advertising and educational efforts have improved clinical practice. Finally, it may reflect local culture; it is our impression that overall sensitivity to this issue at our own institution is high. In support of this idea is the frequency with which sertraline was being prescribed by the consulting services see Table 3 ; . When an SSRI antidepressant seems indicated, our consultation-liaison service almost invariably recommends sertraline in those patients on a large number of medications because of the perception of its lower risk of drug interactions. It would appear that the consulting services were already aware of our preferences in this regard. The potential for P450 drug interactions in patients seen on the consultation-liaison service is significant, necessitating increased vigilance on the part of consultation-liaison psychiatrists and extensive educational efforts for both psychiatric physicians and nonpsychiatric physicians. The authors thank the anonymous reviewer for the very thorough and helpful comments and anacin.
Theophylline xanthine
Five additional studies attempted to clarify the issue of whether MSG induces bronchospasm in asthmatics Table 1 ; . A study by Moneret-Vautrin 1987 ; reported 2 of 30 asthmatic patients undergoing oral challenges with MSG 2.5 g ; developed asthmatic reactions. The author studied patients in a single-blind, placebo-controlled protocol and used declines in PEFR determinations as evidence for asthma attacks. The patients were observed, and hourly PEFR determinations were obtained for 12 h. The two "reactors" were not rechallenged in a double-blind protocol. Furthermore, both patients exhibited wandering baseline PEFR values during their placebo challenges, such that the differences between placebo and MSG PEFR determinations were difficult to detect. One of the two "reactors" was alleged to be sulfite sensitive but "ate frequently in Chinese restaurants without incident." It is not stated whether any other patients had or had not previously experienced asthma attacks in oriental restaurants. The study protocol was unique in that corticosteroid therapy was discontinued 21 d before and theophylline therapy was terminated 3 d before challenges. Because 10 study subjects were said to be intolerant of aspirin and nonsteroidal anti-inflammatory drugs, and another 7 were allergic to house dust, discontinuing antiasthmatic therapy could have led to airway instability and acetaminophen.
159Fluoxetine 160Imipramine Medicines in bipolar disorders 161Lithium carbonate Medicines in anxiety 162Alprazolam MEDICINES ACTING ON RESP.TRACT. Anti-asthma medicines 163Beclomethasone dipropionate 164Salbutamol sulphate 165Salmeterol 166Theophylline compounds Anti-tussive 167Codeine 168Dextromethorphan VITAMINS AND MINERALS 169Calcium salts 170Multivitamin combinations. 171Nicotinamide 172Pyridoxine 173Riboflavine A 176VitaminD3 ergocalciferol.
Theophylline tablet
NON SELF-ADMINISTERED INJECTABLE DRUGS Drug Name STREPTASE SUBLIMAZE SUFENTANIL CITRATE SUPPRELIN SYNERCID SYNTHROID TAGAMET IN SODIUM CHLORIDE TALWIN TAXOL TAZICEF IN DEXTROSE TE ANATOXAL BERNA TENORMIN I.V. TEQUIN BAG TEQUIN VIAL TERRAMYCIN TESTOSTERONE PROPIONATE TETANUS TOXOID FLUID ; THAM THEOPHYLLINE IN 5% DEXTROSE THERACYS THORAZINE THROMBATE III THYMOGLOBULIN TICAR TICE BCG TIMENTIN TNKASE TORADOL TOTACILLIN-N TRAVASOL TRAVASOL TRAVASOL W DEXTROSE TRAVERT TRAVERT IN NORMAL SALINE TRAVERT-1 2NORMAL SALINE W KCL TRAVERT-ELECTROLYTE Generic Name streptokinase fentanyl citrate sufentanil citrate histrelin acetate quinupristin dalfopristin levothyroxine sodium cimetidine hcl normal saline pentazocine lactate paclitaxel semi-synthetic ceftazidime dextrose tetanus toxoid adsorbed atenolol gatifloxacin dextrose 5%-water gatifloxacin oxytetracycline testosterone propionate tetanus toxoid fluid tromethamine theophylline dextrose 5%-water bcg vaccine chlorpromazine hcl antithrombin iii, human lymphocyte immune globulin rabbit ticarcillin disodium bcg vaccine ticarcillin k clavulanate tenecteplase ketorolac tromethamine ampicillin sodium amino acids 85% amino acids 5.5% amino acids in dextrose inverted sugar inverted sugar 10% normal saline inverted sugar 10% normal saline 0.9% potassium chloride electrolyte inv sugar Drug Tier 5 Requirements Limits PA. TABLE 3. Mean urinary recovery of theophylline and its metabolites and clomipramine and theophylline. The fda recommends, healthcare professionals are advised to carefully weigh the potential risks and benefits of using in women during pregnancy and to discuss these findings as well as treatment alternatives with their patients 1. AAPS PharmSciTech 2004; 5 1 ; Article 8 : aapspharmscitech ; . powder dissolution behavior was influenced by processing, drug dissolution at longer intervals 30 and 50 minutes ; remained unaffected Figures 7 and 8 ; . Since all the processed anhydrate samples exhibited similar powder dissolution behavior, the observed differences in tablet dissolution could be attributed to the effect of compression with the most significant effect occurring in the samples subjected to granulation and drying. Figure 8 presents the effects of processing on the dissolution behavior of anhydrous theophylline tablets. The least amount of drug was in solution in the AMA formulation. The decrease in anhydrate crystallinity was brought about by dehydration during drying and resulted in hard tablets. The formation of hard tablets coupled with the rapid conversion to theophylline monohydrate, particularly on the tablet surface, effectively impeded medium penetration into the tablet interior. As a result, the disintegration time is considerably longer Table 2 ; . While the crystallinity of AMAV90 is comparable to that of the unprocessed drug Table 1 ; , only the AMAV90 had undergone anhydrate hydrate anhydrate transition. This sample "history" seems to be responsible for the higher water affinity transformation rate constants in Table 1 ; and, as a consequence, the longer disintegration time Table 2 ; . While the difference in disintegration times translated to small differences in the initial dissolution profiles data not shown ; , the percentage drug dissolved from the AMAV90 tablets was virtually identical to that of the unprocessed drug tablets at 50 minutes Figure 8 ; . When compared with AMA, AMAV90 converted to hydrate at a slower rate Table 1 ; indicating that tablet disintegration preceded substantial surface hydrate formation. When compared with the unprocessed drug, milling for 30 minutes A30 ; caused a pronounced decrease in the degree of crystallinity, increase in surface area and consequently, an increase in the anhydrate hydrate transformation rate constant Table 1 ; . The increased affinity for water could be responsible for the longer disintegration time Table 2 ; . Again, a comparison of this milled sample A30 ; with the dried granules AMAV90 ; provides insight into the effect of sample history. While these 2 samples have nearly the same affinity for water transformation rate constant; Table 1 ; , the AMAV90 tablets have a longer disintegration time. This is particularly noteworthy because AMAV90 also exhibited no amorphous character. In this context, it is also useful to compare the milled anhydrate A30 ; with the granules dried at 50C AMA ; . While both these processing conditions resulted in a loss in crystallinity Table 1 ; , as postulated earlier, the milling-induced decrease in crystallinity may have occurred predominantly on the particle surface, and dehydration was expected to affect both the surface and the bulk. Their differences in affinity for water Table 1 ; might be responsible for the very pronounced differences in disintegration time Table 2 ; and dissolution behavior Figure 8 ; . While a decrease in the crystallinity of the anhydrate could be brought about either by milling A30 ; or by dehydration AMA ; , the effect of these processing conditions on tablet hardness showed pronounced differences. While milling seemed to have a small effect on tablet hardness Table 2 ; , the tablets with the highest hardness were obtained using dried granules AMA ; . Earlier, we had postulated that, when compressed, amorphous compounds predominantly undergo plastic deformation, resulting in hard tablets. This postulate does not seem to hold true when the amorphous character is introduced by milling A30 ; . Mechanical stress is known to result in plastic deformation of anhydrous crystalline theophylline.30 When this material is again subjected to a mechanical stress compression ; , the likelihood of plastic deformation is substantially reduced. As a result, the tablet hardness is comparable with that of the unprocessed anhydrate Table 1 ; . If the above reasoning is correct, then subjecting AMA granules to mechanical stress before they are compressed should decrease the likelihood of plastic deformation during compression and the consequent formation of hard tablets. Hence, AMA granules were milled for 10 minutes and compressed AMA10; Table 2 ; . The resulting tablets had lower hardness values and shorter disintegration times Table 2 ; , and consequently more rapid dissolution than the AMA formulation Figure 8 ; . These results suggest that plastic deformation during compression was unlikely and therefore must have occurred during milling. While a decrease in crystallinity can be brought about either by milling or by granulation, the effect on product performance meas and aralen. Medical research global pandemic hospital areas to what pathogens.
The dental office has proved to be ineffective; or 2 ; Has one or more medical conditions that would create significant or undue medical risk for the individual in the course of delivery of an necessary dental treatment or surgery if not rendered in a hospital or ambulatory surgical center. Prosthetic devices and breast reconstructive surgery incident to the mastectomy. Post-surgical mastectomy care: 1 ; Inpatient hospital coverage for mastectomies that is determined by the treating physician to be medically necessary in accordance with prevailing medical standards and after consultation with the insured patient. 2 ; Outpatient postsurgical follow-up care in keeping with prevailing medical standards by a licensed health care professional qualified to provide postsurgical mastectomy care. The treating physician, after consultation with the insured patient, may choose that the outpatient care be provided at the most medically appropriate setting, which may include the hospital, treating physician's office, outpatient center, or home of the insured patient. Diagnosis and treatment of osteoporosis for high-risk individuals, including, but not limited to, estrogen-deficient individuals who are at clinical risk for osteoporoses, individuals who have vertebrae abnormalities, individuals who are receiving long-term glucocorticoid steroid ; therapy, individuals who have primary hyperparathyroidism and individuals who have a family history of osteoporosis. Treatment of cleft lip and cleft palate for a Dependent child to include medical, dental, speech therapy, audiology, and nutrition services only if such services are prescribed by the treating physician or surgeon and such physician or surgeon certifies that such services are medically necessary and consequent to treatment of the cleft lip or cleft palate. Coverage required by this section is subject to terms and conditions applicable to other benefits.
Drug theophyllineThe American Contact Dermatitis Society's Annual Meeting certifies that this educational activity has been recognized for a maximum of 6 credit hours in Category I and may be applied towards the American Academy of Dermatology Continuing Medical Education Award. Program: 532-100.1. Koch-Wesser J. Serum drug concentrations as therapeutic guides. N Engl J Med 1982; 287: 227-31. Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995; 15: 433-40. Dahlquist R, Billing B, Miners JO, Birkett DJ. Nonlinear metabolic disposition of theophylline. Ther Drug Monit 1984; 6: 290-7. Markham A, Faulds D. Theophyllinw A review of its potential steroid sparing effects in asthma. Drugs 1998; 56: 1081-91. Flink JN, Levy MB, Conard E. Study of two controlled release theophylline preparations. J Med 1990; 25: 58-61. Weinberger M, Hendeles L, Brighley L. The relation of product formulation to absorption of oral theophylline. N Engl J Med 1978; 299: 852. Centre for Drug Evaluation and Research, U.S. Department of Health and Human Services Food and Drug Administration: Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. 2003. 8. Subramaniam S, Garg SK, Dhand R, Malik SK, Sharma PL. Measurement of plasma theophylline concentration by HPLC. Bull P.G.I. 1986; 20: 20-5. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Conference Report: Analytical Method Validation: Bioavailability, Bioequivalence and Pharmacokinetic studies. Pharm Res 1992; 9: 588-92. Win Nonlin, Professional Edition, version 1.5, Pharsight Corp., 800 West Elcamino Real, Suite 200, Mountain View, CA 94040. 11. Bhandari P. Bioequivalence of two brands of sustained release theophylline. J Asso Phys India 1999; 47: 461. Centre for Drug Evaluation and Research, U.S. Department of Health and Human Services Food and Drug Administration: Guidance for Industry: Statistical Approaches to Establishing Bioequivalence-General Considerations. 2001. Home articles health topics diseases & conditions tests & procedures drugs & supplements symptoms site map quick links copd copd stages copd treatment copd symptoms emphysema emphysema symptoms stages of emphysema emphysema treatment spiriva serevent advair diskus theophylline terbutaline terbutaline terbutaline is a prescription drug that is licensed for the treatment of emphysema and asthma and albenza.
| Theophylline toxicity in dogsOur consumer healthcare business is one of the largest consumer health-care companies in the world. The increase in consumer healthcare revenues in 2003, as compared to the prior-year periods, was primarily due to the inclusion of Pharmacia products as well as: the 12% increase in 2003 in sales of Listerine mouthwash, which benefited from the recent U.S. launch of Natural Citrus flavor the favorable impact of the weakening of the U.S. dollar against major currencies.Prevention Role of Healthcare Provider: Provide Selfhelp Tools Self-help tools describe diet, exercise, behavior modification tips, and infant and toddler feeding tips. I think the roots of childhood obesity are within the toddler age group where we are overfeeding our toddlers and allowing them to graze feed with their little bags of Goldfish or Cheerios and the Sippy cups they carry around. Review of mircette in the Brand co-pay. category of contraceptives, oral. This medication is being removed from preferred status because the generic equivalent product, Kariva, is avaiable at at the generic co-pay. In a limited category. |
How long is medication theophylline shelf life
Theophylline canine
Theophylline cr tab
Aristotle timeline, heart murmur thyroid, colostrum early pregnancy, digit 57 inc and postural psoriasis. Flora classique, analgesic balm ointment, advance directives nj and human papilloma virus test or respiratory volumes.
Theophylline monohydrate chemical formula
Drug theophylline medication, theophylline or aminophylline, normal serum theophylline range, theophylline xanthine and theophylline tablet. Drug theophylline, theophylline toxicity in dogs, how long is medication theophylline shelf life and theophylline canine or theophylline cr tab.
